<DOC>
	<DOCNO>NCT00200447</DOCNO>
	<brief_summary>This study conduct fully evaluate way carbidopa/levodopa entacapone may work brain . This research study use [ 123I ] -IBZM dynamic SPECT image determine amount duration dopamine release specific region brain treatment either combination carbidopa/levodopa combination carbidopa/levodopa/entacapone .</brief_summary>
	<brief_title>An Open-Label Feasibility/Pilot Study With 123I-IBZM SPECT ( DOPA-SYN )</brief_title>
	<detailed_description>This pilot evaluation dopaminergic function PD use bolus plus constant infusion protocol [ 123I ] -IBZM SPECT evaluate potential carbidopa/l-dopa alone carbidopa/l-dopa/entacapone produce displacement striatal radioactivity assessment intrasynaptic dopamine . We assess feasibility paradigm detect l-dopa effect SPECT signal subject PD disease duration great 4yrs stable response L-dopa . Each subject undergo three [ 123I ] -IBZM study separate 1-2 week . Subjects medication least 12 h prior study For three scan day patient receive constant intravenous infusion [ 123I ] -IBZM 4-5 hour establish equilibrium bind condition radiotracer striatal D2/D3 receptor . Three baseline SPECT acquisition obtain prior medication dose establish stable baseline . At approximately 5 h initiation infusion subject receive single oral dose either carbidopa/levodopa ( 37.5mg/150mg 50mg/250mg ) , carbidopa/levodopa/entacapone ( either 37.5mg/150mg/200mg- STALEVO 50/250mg/200mg ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dihydroxyphenylalanine</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Main inclusion criterion : The patient age 30 year old . Written inform consent obtain . Patients diagnosis idiopathic Parkinson 's disease . Hoehn Yahr stag patient IIII . Patients diagnosis &gt; 4 yr prior screen Patients treat carbidopa/levodopa &gt; 300 mg levodopa . Main exclusion criterion : The patient atypical druginduced Parkinson 's disease . The patient dementia ( MMSE 24 ) . The patient clinically significant clinical laboratory value , and/or medical psychiatric illness . The patient disorder may interfere drug absorption , distribution , metabolism , excretion ( include gastrointestinal surgery ) . The patient evidence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , neoplastic , endocrine , neurological , immunodeficiency , pulmonary , disorder disease . The patient treat dopamine agonist within past 30 day . Concomitant treatment Monoamine Oxidase ( MAO ) inhibitor ( except selegiline &lt; 10 mg/day ) within 30 day prior screen visit Patient history iodine allergy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Parkinson</keyword>
	<keyword>brain imaging</keyword>
</DOC>